EMERYVILLE, Calif.,
July 28
/PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc.
(Nasdaq: ONXX) today announced that it will host a webcast and
teleconference with management to provide a general business
overview, as well as to discuss second quarter 2010 financial
results, on Wednesday, August 4,
2010, at 5:00 p.m. Eastern
Time (2:00 p.m. Pacific Time).
Financial results for the second quarter ended June 30, 2010 will be released earlier that
day.
Interested parties may access a live webcast of the presentation
on the company's website at:
http://www.onyx-pharm.com/view.cfm/32/Event-Calendar or by dialing
847-619-6547 and using the passcode 27437891. A replay of the
presentation will be available on the Onyx website or by dialing
630-652-3044 and using the passcode 27437891# approximately one
hour after the teleconference concludes. The replay will be
available through August 18,
2010.
About Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company
committed to improving the lives of people with cancer. The
company, in collaboration with Bayer HealthCare Pharmaceuticals,
Inc., is developing and marketing Nexavar® (sorafenib) tablets, a
small molecule drug that is currently approved for the treatment of
liver cancer and advanced kidney cancer. Additionally,
Nexavar is being investigated in several ongoing trials in a
variety of tumor types. Beyond Nexavar, Onyx has established
a development pipeline of anticancer compounds at various stages of
clinical testing, including carfilzomib, a next-generation
proteasome inhibitor, that is currently being evaluated in multiple
clinical trials for the treatment of patients with relapsed or
relapsed/refractory multiple myeloma and solid tumors. ONX
0801, an alpha-folate receptor targeted inhibitor of the
thymidylate synthase, and ONX 0912, an oral proteasome inhibitor,
are currently in Phase 1 testing. For more information about
Onyx, visit the company's website at www.onyx-pharm.com.
Nexavar® (sorafenib) tablets is a registered trademark of Bayer
HealthCare Pharmaceuticals, Inc.
SOURCE Onyx Pharmaceuticals, Inc.